{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:40:17Z","timestamp":1791247217881,"version":"4.1.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-ioi260002-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>High prescription drug costs are a pressing national concern and contribute to medication nonadherence and poor health outcomes. The Inflation Reduction Act (IRA) introduced sweeping reforms to improve medication affordability, but their potential impact on medication adherence is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association of the IRA\u2019s 2024 prescription drug provisions with cost-related medication nonadherence as well as health care\u2013related financial strain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This quasi-experimental difference-in-differences analysis used data from the 2021-2024 National Health Interview Survey. Adults aged 62 to 67 years who were enrolled in Medicare Part D (intervention) or private insurance (comparator) were included. Individuals with incomes 135% or less of the federal poverty level, dually enrolled in Medicaid, and who currently used insulin were excluded from the primary analysis because preexisting protections limited their out-of-pocket spending in Medicare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>The IRA\u2019s prescription drug provisions were enacted on January 1, 2024, including (1) elimination of the 5% coinsurance requirement for catastrophic coverage that effectively capped out-of-pocket drug costs to approximately $3300 per year and (2) expansion of full low-income subsidies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was cost-related medication nonadherence. The secondary outcome was health care\u2013related financial strain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population included 1454 Medicare beneficiaries (weighted mean [SD] age, 66.1 [0.8] years; 53.1% female) and 3797 privately insured comparators (weighted mean [SD] age, 63.3 [1.2] years; 50.7% female). Prior to the 2024 IRA reforms, trends in cost-related medication nonadherence were parallel between the 2 groups. Following implementation of the IRA\u2019s 2024 provisions, cost-related medication nonadherence declined among Medicare beneficiaries relative to comparators (adjusted difference-in-differences estimate, \u22124.9 percentage points [pp]; 95% CI, \u22128.8 to \u22121.0 pp). Among Medicare beneficiaries with multiple chronic conditions, the decline was more pronounced (adjusted difference-in-differences estimate, \u22127.8 pp; 95% CI, \u221212.9 to \u22122.8 pp). These findings were robust across multiple sensitivity analyses as well as secondary analyses using Medicare beneficiaries with incomes 135% or less of the federal poverty level and dually enrolled in Medicaid as an alternative comparator group. In contrast, there were no meaningful differential changes observed for health care\u2013related financial strain (adjusted difference-in-differences estimate, \u22122.6 pp; 95% CI, \u221210.1 to 5.0 pp).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ioi260002-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this difference-in-differences analysis, the IRA\u2019s 2024 prescription drug provisions were associated with a reduction in cost-related medication nonadherence among eligible Medicare beneficiaries in their first year. These early improvements may have important implications for chronic disease management and downstream clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.0012","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:00:34Z","timestamp":1773068434000},"page":"609","source":"Crossref","is-referenced-by-count":10,"title":["Cost-Related Medication Nonadherence After the Inflation Reduction Act"],"prefix":"10.1001","volume":"186","author":[{"given":"Lucas X.","family":"Marinacci","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mein","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi K.","family":"Wadhera","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6.9","key":"ioi260002r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1939","article-title":"Changes in health care and prescription medication affordability in the US during the COVID-19 pandemic.","volume":"5","author":"Mein","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"16","key":"ioi260002r3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJMp2211223","article-title":"Impending relief for Medicare beneficiaries\u2014the Inflation Reduction Act.","volume":"387","author":"Dusetzina","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi260002r9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11606-024-09063-4","article-title":"Out-of-pocket prescription drug savings for Medicare beneficiaries with asthma and COPD under the Inflation Reduction Act.","volume":"40","author":"Mein","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"15","key":"ioi260002r10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2023.02.002","article-title":"Out-of-pocket drug costs for Medicare beneficiaries with cardiovascular risk factors under the Inflation Reduction Act.","volume":"81","author":"Narasimmaraj","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ioi260002r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5058","article-title":"Changes in health care access and preventive health screenings by race and ethnicity.","volume":"5","author":"Alba","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"7","key":"ioi260002r12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamainternmed.2024.1464","article-title":"Financial burden of health care in the privately insured US population.","volume":"184","author":"Shashikumar","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"5","key":"ioi260002r13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s11606-022-07406-7","article-title":"Racial\/ethnic disparities in delaying or not receiving medical care during the COVID-19 pandemic.","volume":"37","author":"Ahmed","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"10","key":"ioi260002r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004083","article-title":"Medicare eligibility and healthcare access, affordability, and financial strain for low- and higher-income adults in the United States: a regression discontinuity analysis.","volume":"19","author":"Aggarwal","year":"2022","journal-title":"PLoS Med"},{"issue":"8","key":"ioi260002r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25280","article-title":"Health outcome changes in individuals with type 1 diabetes after a state-level insulin copayment cap.","volume":"7","author":"Giannouchos","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"ioi260002r17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1377\/hlthaff.2024.00118","article-title":"State out-of-pocket caps on insulin costs: no significant increase in claims or utilization.","volume":"43","author":"Anderson","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"ioi260002r18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.7326\/M23-1965","article-title":"Association of state insulin out-of-pocket caps with insulin cost-sharing and use among commercially insured patients with diabetes: a pre-post study with a control group.","volume":"177","author":"Garabedian","year":"2024","journal-title":"Ann Intern Med"},{"issue":"1","key":"ioi260002r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.51208","article-title":"Estimates of insulin out-of-pocket cap\u2013associated prescription satisfaction, adherence, and affordability among Medicare beneficiaries.","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"ioi260002r21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1077558712457595","article-title":"Validity of reported Medicare Part D enrollment in the Medical Expenditure Panel Survey.","volume":"69","author":"Hill","year":"2012","journal-title":"Med Care Res Rev"},{"issue":"23-24","key":"ioi260002r23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70247","article-title":"Difference-in-differences for health policy and practice: a review of modern methods.","volume":"44","author":"Feng","year":"2025","journal-title":"Stat Med"},{"key":"ioi260002r24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40471-023-00327-x","article-title":"A tutorial on applying the difference-in-differences method to health data.","volume":"11","author":"Rothbard","year":"2023","journal-title":"Curr Epidemiol Rep"},{"issue":"16","key":"ioi260002r27","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1001\/jama.299.16.1922","article-title":"Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.","volume":"299","author":"Madden","year":"2008","journal-title":"JAMA"},{"issue":"7","key":"ioi260002r29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jama.2023.12951","article-title":"Insulin fills by Medicare enrollees and out-of-pocket caps under the Inflation Reduction Act.","volume":"330","author":"Myerson","year":"2023","journal-title":"JAMA"},{"issue":"23","key":"ioi260002r30","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2024.7348","article-title":"Shingles vaccination in Medicare Part D after Inflation Reduction Act elimination of cost sharing.","volume":"331","author":"Qato","year":"2024","journal-title":"JAMA"},{"issue":"13","key":"ioi260002r31","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s11606-025-09486-7","article-title":"Prescription drug savings with the expansion of the out-of-pocket spending cap to adults with private insurance.","volume":"40","author":"Johnson","year":"2025","journal-title":"J Gen Intern Med"},{"issue":"4","key":"ioi260002r33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.123.010149","article-title":"Policy strategies to advance cardiovascular health in the United States\u2014building on a century of progress.","volume":"17","author":"Wadhera","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"ioi260002r34","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2023.4018","article-title":"The US health equity crisis\u2014an economic case for a moral imperative?","volume":"329","author":"Wadhera","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"ioi260002r35","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamacardio.2020.3638","article-title":"Quality of care and outcomes among Medicare Advantage vs fee-for-service Medicare patients hospitalized with heart failure.","volume":"5","author":"Figueroa","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"ioi260002r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15227","article-title":"Comparison of Medicare Advantage vs traditional Medicare for health care access, affordability, and use of preventive services among adults with low income.","volume":"5","author":"Aggarwal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ioi260002r37","doi-asserted-by":"publisher","first-page":"r1702","DOI":"10.1136\/bmj.r1702","article-title":"The United States faces a healthcare affordability crisis.","volume":"390","author":"Liu","year":"2025","journal-title":"BMJ"},{"key":"ioi260002r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084803","article-title":"Patient healthcare spending after the No Surprises Act: quasi-experimental difference-in-differences study.","volume":"390","author":"Liu","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"ioi260002r39","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1377\/hlthaff.2024.01527","article-title":"Medicare Part D redesign savings may be lower for beneficiaries with spending below the out-of-pocket cap.","volume":"44","author":"Dusetzina","year":"2025","journal-title":"Health Aff (Millwood)"},{"issue":"20","key":"ioi260002r40","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMsa2414435","article-title":"Loss of subsidized drug coverage and mortality among Medicare beneficiaries.","volume":"392","author":"Roberts","year":"2025","journal-title":"N Engl J Med"},{"issue":"21","key":"ioi260002r41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.jacc.2023.03.414","article-title":"The Inflation Reduction Act and out-of-pocket drug costs for Medicare beneficiaries with cardiovascular disease.","volume":"81","author":"Kazi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"ioi260002r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16290","article-title":"Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes.","volume":"6","author":"Essien","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ioi260002r43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ahj.2020.06.012","article-title":"Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease.","volume":"228","author":"Lauffenburger","year":"2020","journal-title":"Am Heart J"},{"issue":"5","key":"ioi260002r44","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/MLR.0000000000000701","article-title":"A comparison of self-reported medication adherence to concordance between Part D claims and medication possession.","volume":"55","author":"Savitz","year":"2017","journal-title":"Med Care"},{"key":"ioi260002r1","unstructured":"Sparks? G, Kirzinger? A, Montero? A, Valdes? I, Hamel? L. Public opinion on prescription drugs and their prices. KFF. October 4, 2024. Accessed February 4, 2026. https:\/\/www.kff.org\/health-costs\/public-opinion-on-prescription-drugs-and-their-prices\/"},{"key":"ioi260002r4","unstructured":"Inflation Reduction Act of 2022, HR 5376, 117th Cong (2021-2022). Pub L No. 117-169. Accessed August 8, 2025. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376\/text"},{"key":"ioi260002r5","unstructured":"Inflation Reduction Act: CMS implementation timeline. Centers for Medicare & Medicaid Services. Accessed July 23, 2025. https:\/\/www.cms.gov\/files\/document\/10522-inflation-reduction-act-timeline.pdf"},{"key":"ioi260002r6","unstructured":"Cubanski? J, Neuman? T. What to know about Medicare Part D premiums. KFF. August 1, 2024. Accessed July 23, 2025. https:\/\/www.kff.org\/medicare\/what-to-know-about-medicare-part-d-premiums\/"},{"key":"ioi260002r7","unstructured":"Projecting the impact of the $2,000 Part D out-of-pocket cap for Medicare Part D enrollees with high prescription drug spending. US Department of Health and Human Services. January 13, 2025. Accessed July 23, 2025. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/ee9b0f2bf15e69d7e3c7ca7618eaa2af\/projecting-impact-part-d.pdf"},{"key":"ioi260002r8","unstructured":"Sayed? BA, Finegold? K, Olsen? TA, . Medicare Part D enrollee out-of-pocket spending: recent trends and projected impacts of the Inflation Reduction Act. US Department of Health and Human Services. July 7, 2023. Updated January 30, 2024. Accessed July 23, 2024. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/1b652899fb99dd7e6e0edebbcc917cc8\/aspe-part-d-oop.pdf"},{"key":"ioi260002r15","unstructured":"About NHIS. National Center for Health Statistics. November 20, 2024. Accessed July 23, 2025. https:\/\/www.cdc.gov\/nchs\/nhis\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/nchs\/nhis\/about_nhis.htm"},{"key":"ioi260002r19","unstructured":"Sayed? BA, Finegold? K, Olsen? TA, . Insulin affordability and the Inflation Reduction Act: Medicare beneficiary savings by state and demographics. US Department of Health and Human Services. January 24, 2023. Accessed August 8, 2025. https:\/\/aspe.hhs.gov\/reports\/insulin-affordability-ira-data-point"},{"key":"ioi260002r22","unstructured":"Feyman? Y, Ruhter? J, Finegold? K, . Medicare enrollees and the Part D drug benefit: improving financial protection through the low-income subsidy. US Department of Health and Human Services. February 2024. Accessed November 26, 2025. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/1b1f69ae062bac6482241b17a6a7f17e\/lis-issue-brief.pdf"},{"key":"ioi260002r25","unstructured":"Baker? A, Callaway? B, Cunningham? S, Goodman-Bacon? A, Sant\u2019Anna? PHC. Difference-in-differences designs: a practitioner\u2019s guide.? arXiv. Preprint posted online March 17, 2025. https:\/\/arxiv.org\/abs\/2503.13323"},{"key":"ioi260002r26","unstructured":"Posit website. Accessed February 4, 2026. http:\/\/www.posit.co\/"},{"key":"ioi260002r28","unstructured":"Finegold? K, King? KL, Sayed? BA, Zuckerman? R. Medicare Part D enrollees reaching the out-of-pocket limit by June 2024. US Department of Health and Human Services. October 22, 2024. Accessed February 4, 2026. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/757a8acd9b7c4f44a4a4bbfa41d5831c\/oop-cap-ib.pdf"},{"key":"ioi260002r32","unstructured":"Leonard? F, Jacobson? G, Collins? SR, Shah? A, Haynes? LA. Medicare\u2019s affordability problem: a look at the cost burdens faced by older enrollees. The Commonwealth Fund. September 19, 2023. Accessed August 2, 2025. https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2023\/sep\/medicare-affordability-problem-cost-burdens-biennial"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2846009\/jamainternal_marinacci_2026_oi_260002_1777045091.90738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:01:33Z","timestamp":1777906893000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2846009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.0012","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}